论文部分内容阅读
重组人血管内皮抑制素(恩度)是我国自主研发的新型人血管内皮抑制素,临床研究已明确了其安全性和有效性,恩度联合化疗治疗晚期NSCLC能显著提高客观疗效。本文就我院应用恩度联合铂类化疗药物治疗50例晚期NSCLC患者的临床资料进行回顾性分析。报告如下。1资料与方法1.1临床资料2008年6月至2012年6月我科收治的NSCLC患者50例,男33例、女17例,年龄44~78岁、中位数年龄59岁,均经病理组织学或细胞学检查确诊,其中病理分型为腺癌30例、鳞癌12例、大细胞癌5例、其他类型癌3例;
Recombinant human endostatin (Endostar) is a new type of human endostatin developed independently in our country. Clinical studies have confirmed its safety and effectiveness. Endostar combined with chemotherapy can significantly improve the objective effect of advanced NSCLC. This article retrospectively analyzed the clinical data of 50 patients with advanced NSCLC treated with Endostar combined with platinum-based chemotherapy in our hospital. The report is as follows. 1 Materials and Methods 1.1 Clinical data June 2008 to June 2012 NSCLC patients admitted to our department 50 patients, 33 males and 17 females, aged 44 to 78 years, the median age of 59 years, were pathologically Learning or cytology confirmed diagnosis, including pathological classification of adenocarcinoma in 30 cases, squamous cell carcinoma in 12 cases, 5 cases of large cell carcinoma, 3 cases of other types of cancer;